Characterization of group I introns in generating circular RNAs as vaccines

Page view(s)
0
Checked on
Characterization of group I introns in generating circular RNAs as vaccines
Title:
Characterization of group I introns in generating circular RNAs as vaccines
Journal Title:
Nucleic Acids Research
Publication Date:
04 March 2025
Citation:
Liao, K.-C., Eshaghi, M., Hong, Z., Saw, T., Lim, J., Han, J., Aw, J., Tan, K., Yap, A., Gao, X., Cheng, Y., Lim, S., Cheang, Y., Saron, W. A., Rathore, A. S., Zhang, L., Shunmuganathan, B., Gupta, R., Tan, S., et al. (2025). Characterization of group I introns in generating circular RNAs as vaccines. Nucleic Acids Research, 53(4). https://doi.org/10.1093/nar/gkaf089
Abstract:
Abstract Circular RNAs are an increasingly important class of RNA molecules that can be engineered as RNA vaccines and therapeutics. Here, we screened eight different group I introns for their ability to circularize and delineated different features that are important for their function. First, we identified the Scytalidium dimidiatum group I intron as causing minimal innate immune activation inside cells, underscoring its potential to serve as an effective RNA vaccine without triggering unwanted reactogenicity. Additionally, mechanistic RNA structure analysis was used to identify the P9 domain as important for circularization, showing that swapping sequences can restore pairing to improve the circularization of poor circularizers. We also determined the diversity of sequence requirements for the exon 1 and exon 2 (E1 and E2) domains of different group I introns and engineered a S1 tag within the domains for positive purification of circular RNAs. In addition, this flexibility in E1 and E2 enables substitution with less immunostimulatory sequences to enhance protein production. Our work deepens the understanding of the properties of group I introns, expands the panel of introns that can be used, and improves the manufacturing process to generate circular RNAs for vaccines and therapeutics.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research / project is supported by the A*STAR, National Research Foundation of Singapore, EMBO Young Investigatorship, Wellcome Leap R3 program - Industry Alignment Fund - Pre-Positioning, Competitive Research Programme
Grant Reference no. : HHP IAF-PP Programme (H22J1a0050), NRF grant NRF-CRP27-2021-0003.
Description:
©The Author(s) 2025. Published by Oxford University Press on behalf of Nucleic Acids Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https: // creativecommons.org / licenses / by / 4.0 / ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN:
0305-1048
1362-4962
Files uploaded: